{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-007445","form_type":"8-K","ticker":null,"cik":"0001404935","company_name":"THC Therapeutics, Inc.","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.927739+00:00","generated_at":"2026-06-10T03:19:36.738037+00:00","sec_items":["3.02","5.02","5.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"THC Therapeutics CEO resigns; Scott Cox appointed interim CEO; change of control via preferred stock","bullets":["Brandon Romanek resigned as CEO on Sept 29, 2023; Scott Cox appointed Interim CEO and board member.","Cox received 600,000 Series A Preferred shares at $0.30 each, each with 100 votes and convertible to 100 common shares.","Preferred stock issuance constitutes a change of control of THC Therapeutics.","Cox has over 20 years experience; currently CEO of Verde Bio Holdings (OTC: VBHI).","Shares were issued under Section 4(a)(2) and Rule 506(b) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-007445","json":"https://secwatch.observer/filing/0001477932-23-007445.json","markdown":"https://secwatch.observer/filing/0001477932-23-007445.md","text":"https://secwatch.observer/filing/0001477932-23-007445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404935/000147793223007445/0001477932-23-007445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404935/000147793223007445/thct_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:19:36.738037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a4d58244c","claim":"Scott Cox was appointed as Interim Chief Executive Officer at THC Therapeutics, Inc..","evidence_excerpt":"Scott Cox was appointed as Interim CEO of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404935/000147793223007445/0001477932-23-007445-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"91626d8c22","claim":"Scott Cox was appointed as Member of the Board of Directors at THC Therapeutics, Inc..","evidence_excerpt":"as a member of its Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404935/000147793223007445/0001477932-23-007445-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"cb9d757fd4","claim":"Brandon Romanek resigned as Chief Executive Officer at THC Therapeutics, Inc..","evidence_excerpt":"On September 29, 2023, Brandon Romanek resigned as CEO of THC Therapeutics, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404935/000147793223007445/0001477932-23-007445-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}